1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Neurological conditions
  5. Multiple sclerosis

Ocrelizumab for treating relapsing–remitting multiple sclerosis

Technology appraisal guidance [TA533] Published date: 25 July 2018

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Documents

A list of downloadable documents created during development.

Expected publication

  • Equality Impact Assessment (Guidance development) PDF 230.49 KB 25 July 2018  

Final appraisal determination

  • Final appraisal determination  
  • Final appraisal determination document PDF 504.18 KB 22 June 2018  
  • Public committee slides PDF 435.54 KB 22 June 2018  
  • Committee papers PDF 4.43 MB 22 June 2018  

Appraisal consultation

  • Appraisal consultation  
  • Appraisal consultation document PDF 427.71 KB 05 April 2018  
  • Public committee slides PDF 1.03 MB 05 April 2018  
  • Committee papers PDF 22.75 MB 05 April 2018  

Invitation to participate

  • Final scope PDF 108.63 KB 03 October 2017  
  • Final matrix PDF 251.61 KB 03 October 2017  
  • Equality impact assessment (Scoping) PDF 173.82 KB 26 September 2017  
  • NICE's response to comments on the draft scope and provisional matrix PDF 489.54 KB 03 October 2018  

Draft scope documents

  • Draft scope (pre-referral) PDF 131.15 KB 31 January 2017  
  • Provisional matrix (pre-referral) PDF 37.24 KB 31 January 2017